Explore
Validate
Learn
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [12]
- Comments [0]
- Validations
- Western blot [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 17758-1-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#17758-1-AP, RRID:AB_2261476
- Product name
- DCK antibody
- Antibody type
- Polyclonal
- Description
- KD/KO validated DCK antibody (Cat. #17758-1-AP) is a rabbit polyclonal antibody that shows reactivity with human and has been validated for the following applications: WB,ELISA.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references Targeting FN1 to overcome gemcitabine resistance in gallbladder cancer: Mechanistic insights and an iRGD-modified PEG-PLGA nanoparticle delivery strategy.
Nanomagnetic Hyperthermia Sensitizes Gemcitabine Chemosensitivity in Pancreatic Cancer by Inhibiting HSPB1 to Amplify ACSL4-Mediated Ferroptosis.
Combining the novel FLT3 and MERTK dual inhibitor MRX-2843 with venetoclax results in promising antileukemic activity against FLT3-ITD AML.
All Blood Brain Barrier Cell Types Demonstrate Capability to Influence Differential Tenofovir and Emtricitabine Metabolism and Transport in the Brain.
A pyrimidine metabolism-related signature for prognostic and immunotherapeutic response prediction in hepatocellular carcinoma by integrating analyses.
Abrogation of ARF6 in promoting erastin-induced ferroptosis and mitigating capecitabine resistance in gastric cancer cells.
Adult T-cell leukemia-lymphoma acquires resistance to DNA demethylating agents through dysregulation of enzymes involved in pyrimidine metabolism.
m(6)A Methyltransferase METTL14-Mediated Upregulation of Cytidine Deaminase Promoting Gemcitabine Resistance in Pancreatic Cancer.
KNSTRN promotes tumorigenesis and gemcitabine resistance by activating AKT in bladder cancer.
Drug-repositioning screening identified fludarabine and risedronic acid as potential therapeutic compounds for malignant pleural mesothelioma.
Abrogation of ARF6 promotes RSL3-induced ferroptosis and mitigates gemcitabine resistance in pancreatic cancer cells.
Using RNA-seq and targeted nucleases to identify mechanisms of drug resistance in acute myeloid leukemia.
Tian M, Meng X, Song W, Wu Z, Liu Y, Dong X, Ren S, Du J, Zhao P
Materials today. Bio 2026 Apr;37:102877
Materials today. Bio 2026 Apr;37:102877
Nanomagnetic Hyperthermia Sensitizes Gemcitabine Chemosensitivity in Pancreatic Cancer by Inhibiting HSPB1 to Amplify ACSL4-Mediated Ferroptosis.
Ren J, Wu S, Su T, Li H, Ding J, Chen F, Mo J, Li J, Wang Z, Han L, Wu Z
Small (Weinheim an der Bergstrasse, Germany) 2026 Apr;22(22):e14973
Small (Weinheim an der Bergstrasse, Germany) 2026 Apr;22(22):e14973
Combining the novel FLT3 and MERTK dual inhibitor MRX-2843 with venetoclax results in promising antileukemic activity against FLT3-ITD AML.
Wu S, Liu F, Gai Y, Carter J, Edwards H, Hüttemann M, Wang G, Li C, Taub JW, Wang Y, Ge Y
Leukemia research 2024 Sep;144:107547
Leukemia research 2024 Sep;144:107547
All Blood Brain Barrier Cell Types Demonstrate Capability to Influence Differential Tenofovir and Emtricitabine Metabolism and Transport in the Brain.
Wilkins HN, Knerler SA, Warshanna A, Colón Ortiz R, Haas K, Orsburn BC, Williams DW
ACS pharmacology & translational science 2024 Nov 8;7(11):3626-3640
ACS pharmacology & translational science 2024 Nov 8;7(11):3626-3640
A pyrimidine metabolism-related signature for prognostic and immunotherapeutic response prediction in hepatocellular carcinoma by integrating analyses.
Zhang S, Qin O, Wu S, Xu H, Huang W, Hailiang S
Aging 2024 Mar 15;16(6):5545-5566
Aging 2024 Mar 15;16(6):5545-5566
Abrogation of ARF6 in promoting erastin-induced ferroptosis and mitigating capecitabine resistance in gastric cancer cells.
Geng D, Wu H
Journal of gastrointestinal oncology 2022 Jun;13(3):958-967
Journal of gastrointestinal oncology 2022 Jun;13(3):958-967
Adult T-cell leukemia-lymphoma acquires resistance to DNA demethylating agents through dysregulation of enzymes involved in pyrimidine metabolism.
Yoshida-Sakai N, Watanabe T, Yamamoto Y, Ureshino H, Kamachi K, Kurahashi Y, Fukuda-Kurahashi Y, Kimura S
International journal of cancer 2022 Apr 1;150(7):1184-1197
International journal of cancer 2022 Apr 1;150(7):1184-1197
m(6)A Methyltransferase METTL14-Mediated Upregulation of Cytidine Deaminase Promoting Gemcitabine Resistance in Pancreatic Cancer.
Zhang C, Ou S, Zhou Y, Liu P, Zhang P, Li Z, Xu R, Li Y
Frontiers in oncology 2021;11:696371
Frontiers in oncology 2021;11:696371
KNSTRN promotes tumorigenesis and gemcitabine resistance by activating AKT in bladder cancer.
Xiong Y, Ju L, Yuan L, Chen L, Wang G, Xu H, Peng T, Luo Y, Xiao Y, Wang X
Oncogene 2021 Mar;40(9):1595-1608
Oncogene 2021 Mar;40(9):1595-1608
Drug-repositioning screening identified fludarabine and risedronic acid as potential therapeutic compounds for malignant pleural mesothelioma.
Dell'Anno I, Martin SA, Barbarino M, Melani A, Silvestri R, Bottaro M, Paolicchi E, Corrado A, Cipollini M, Melaiu O, Giordano A, Luzzi L, Gemignani F, Landi S
Investigational new drugs 2021 Jun;39(3):644-657
Investigational new drugs 2021 Jun;39(3):644-657
Abrogation of ARF6 promotes RSL3-induced ferroptosis and mitigates gemcitabine resistance in pancreatic cancer cells.
Ye Z, Hu Q, Zhuo Q, Zhu Y, Fan G, Liu M, Sun Q, Zhang Z, Liu W, Xu W, Ji S, Yu X, Xu X, Qin Y
American journal of cancer research 2020;10(4):1182-1193
American journal of cancer research 2020;10(4):1182-1193
Using RNA-seq and targeted nucleases to identify mechanisms of drug resistance in acute myeloid leukemia.
Rathe SK, Moriarity BS, Stoltenberg CB, Kurata M, Aumann NK, Rahrmann EP, Bailey NJ, Melrose EG, Beckmann DA, Liska CR, Largaespada DA
Scientific reports 2014 Aug 13;4:6048
Scientific reports 2014 Aug 13;4:6048
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The DCK antibody from Proteintech is a rabbit polyclonal antibody to a recombinant protein of human DCK. This antibody recognizes human,mouse,rat antigen. The DCK antibody has been validated for the following applications: ELISA, WB analysis.
